"A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma after 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide"

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-523815-12-00

Enrollment

181

Registered

2026-07-01

Start date

Unknown

Completion date

Unknown

Last updated

2026-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed or Refractory Multiple Myeloma

Brief summary

Dual primary endpoints: CR or better, PFS

Interventions

DRUGteclistamab

DRUGJNJ-79635322

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Dual primary endpoints: CR or better, PFS	—

Outcome results

None listed

Source: EU CTIS · Data processed: Jul 4, 2026